Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 60.5%

Neg 60.5% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.